Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis

Table 4 Baseline characteristics in patients with different response to treatment

Characteristic	Remission, n = 145	Non-remission, n = 113	p value
Age, yr	55 (45, 62)	57 (51, 67)	0.003
Male, n (%)	100 (69)	76 (67.3)	0.770
Systolic BP, mmHg	130 (113, 140)	131 (118.5, 142)	0.203
Diastolic BP, mmHg	79.65 ± 13.10	80.24 ± 15.44	0.089
Serum cholesterol, mmol/L	6.80 (5.48, 8.28)	6.89 (5.80, 8.64)	0.432
Serum creatinine, µmol/L	83 (68.5, 96.5)	80 (67, 92.5)	0.643
Serum albumin, g/L	24.9 ± 5.5	23.8 ± 4.9	0.227
eGFR, mL/min/1.73m²	90.6 (71.3, 101.8)	90.5 (72.7, 99.3)	0.609
UPCR, g/g	4.22 (3.53, 5.68)	4.24 (3.52, 5.28)	0.796
Anti-PLA2R-Ab-positive, n (%)^a	100/124 (80.6)	67/79 (84.8)	0.449
Anti-PLA2R-Ab titer, RU/ml	41.10 (4.56, 110.63)	70.86 (22.26, 156.34)	0.015
ACE inhibitor/ARB use, n (%)	77 (53.1)	63 (55.8)	0.672
Treatment			0.008
CNI, n (%)	39 (26.9)	47 (41.6)	0.013
CTX, n (%)	47 (32.4)	39 (34.5)	0.723
RTX, n (%)	49 (40.7)	27 (23.9)	0.005
Prior immunosuppressive therapy, n (%)	51 (35.2)	34 (30.1)	0.389
Follow-up, mo	15 (12, 24)	12 (6, 15)	< 0.001

Data were shown as n (%), median (IQR) or mean ± SD. ^aA part of patients lack baseline anti-PLA2R-Ab tests, were shown as n/N. ACE, angiotensin-converting enzyme; ARB, angiotensin 2 receptor blocker; BP, blood pressure; CNI, calcineurin inhibitor; CTX, cyclophosphamide; eGFR, estimated glomerular filtration rate; anti-PLA2R-Ab, anti-M-type phospholipase A2 receptor antibody; RTX, rituximab; UPCR, urine protein-to-creatinine ratio

ISSN: 1471-2369